- JP-listed companies
- Income statement
(4888) Income statement
Market cap
¥10.4B
P/E ratio
-17.8x
Develops BNCT cancer treatment that uses boron and neutrons to selectively destroy cancer cells while minimizing damage to healthy tissue.
| 2015/12 | 2016/12 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 418 | 145 | - | - | - | 206 | 100 | 229 | 269 | 961 | 323 |
| Revenue growth (%) | - | - | - | - | - | ||||||
| Gross profit | - | - | - | - | - | 182 | 85 | 207 | 217 | 846 | 279 |
| Gross margin (%) | - | - | - | - | - | ||||||
| Operating margin (%) | - | - | - | - | - | ||||||
| Operating expenses | - | - | - | 861 | 951 | 862 | 827 | 1,014 | 978 | 936 | 1,028 |
| Operating income | - | - | - | -861 | -951 | -681 | -742 | -807 | -760 | -90 | -748 |
| Income before tax | 29 | -440 | -1,052 | -856 | -959 | -656 | -764 | -776 | -760 | -138 | -778 |
| Pretax margin (%) | 7 | -303.8 | - | - | - | -318.7 | -763.4 | -338.8 | -282.1 | -14.3 | -240.6 |
| Provision for income taxes | - | - | - | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 |
| Effective tax rate (%) | - | - | - | ||||||||
| Net income | 19 | -298 | -1,055 | -859 | -962 | -659 | -768 | -779 | -764 | -141 | -780 |
| Earnings per share | 9,710.27 | -2,963.82 | -8,137.76 | -66.28 | -61.68 | -32.9 | -27.34 | -26.97 | -24.66 | -4.22 | -22.95 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - |